RICCIO, ELEONORA
 Distribuzione geografica
Continente #
AS - Asia 3.201
EU - Europa 2.589
NA - Nord America 2.465
SA - Sud America 436
AF - Africa 114
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
AN - Antartide 1
Totale 8.814
Nazione #
US - Stati Uniti d'America 2.339
SG - Singapore 1.696
RU - Federazione Russa 1.302
CN - Cina 734
IT - Italia 624
VN - Vietnam 361
BR - Brasile 328
HK - Hong Kong 203
DE - Germania 140
IE - Irlanda 84
FI - Finlandia 74
NL - Olanda 72
GB - Regno Unito 70
CA - Canada 66
FR - Francia 57
AR - Argentina 47
MX - Messico 47
IN - India 41
CI - Costa d'Avorio 40
UA - Ucraina 38
ZA - Sudafrica 36
PL - Polonia 28
KR - Corea 26
SE - Svezia 23
JP - Giappone 21
BD - Bangladesh 20
EC - Ecuador 19
ES - Italia 15
TR - Turchia 12
AT - Austria 11
BG - Bulgaria 10
CO - Colombia 10
ID - Indonesia 10
NP - Nepal 8
IL - Israele 7
IQ - Iraq 7
LT - Lituania 7
MA - Marocco 7
PE - Perù 7
UY - Uruguay 7
UZ - Uzbekistan 7
VE - Venezuela 7
KG - Kirghizistan 6
PK - Pakistan 6
RO - Romania 6
KE - Kenya 5
TN - Tunisia 5
BE - Belgio 4
CH - Svizzera 4
EG - Egitto 4
ET - Etiopia 4
IR - Iran 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
DZ - Algeria 3
EU - Europa 3
JO - Giordania 3
KZ - Kazakistan 3
MN - Mongolia 3
MY - Malesia 3
NO - Norvegia 3
SA - Arabia Saudita 3
AU - Australia 2
BH - Bahrain 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GY - Guiana 2
JM - Giamaica 2
KH - Cambogia 2
LV - Lettonia 2
NG - Nigeria 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AI - Anguilla 1
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BZ - Belize 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
GR - Grecia 1
HN - Honduras 1
IM - Isola di Man 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
ME - Montenegro 1
MG - Madagascar 1
ML - Mali 1
MQ - Martinica 1
Totale 8.801
Città #
Singapore 766
Moscow 308
Ashburn 269
Beijing 269
Chandler 222
Hong Kong 203
Hefei 148
Santa Clara 138
Napoli 129
Dong Ket 124
Naples 111
Los Angeles 95
Ho Chi Minh City 93
Millbury 82
Munich 59
Amsterdam 54
Des Moines 53
Dublin 52
New York 49
Boston 44
Nanjing 42
Princeton 41
Redondo Beach 41
São Paulo 38
Buffalo 36
Hanoi 34
Lawrence 32
San Jose 31
Montreal 25
Seoul 25
Caserta 24
Warsaw 24
Wilmington 24
Milan 23
Orem 23
Buenos Aires 22
Mexico City 21
Seattle 21
Haiphong 20
Helsinki 19
Johannesburg 19
Washington 19
Tokyo 18
Turku 18
Denver 17
London 17
Nuremberg 17
Dallas 15
The Dalles 15
Ottawa 14
Poplar 14
Rome 14
Stockholm 14
Houston 13
Jacksonville 13
Chicago 12
Falkenstein 12
Frankfurt am Main 12
Hebei 12
Rio de Janeiro 12
Toronto 12
Atlanta 11
Brooklyn 11
Da Nang 11
Biên Hòa 10
Hải Dương 10
Nanchang 10
Sciacca 10
Chennai 9
Duncan 9
Düsseldorf 9
Manchester 9
Phoenix 9
Redwood City 9
Sofia 9
Jiaxing 8
Tianjin 8
Boardman 7
Campinas 7
Montevideo 7
Ninh Bình 7
Querétaro 7
Quito 7
San Francisco 7
Tashkent 7
Belo Horizonte 6
Brasília 6
Changsha 6
Fairfield 6
Florence 6
Istanbul 6
Kyiv 6
Shenyang 6
Bishkek 5
Bogotá 5
Charleston 5
Elk Grove Village 5
Guarulhos 5
Hangzhou 5
Lauterbourg 5
Totale 4.434
Nome #
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 207
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 152
Evidence That p-Cresol and IL-6 Are Adsorbed by the HFR Cartridge: Towards a New Strategy to Decrease Systemic Inflammation in Dialyzed Patients? 146
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 146
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 145
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 134
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 133
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 131
Current tissue molecular markers in colorectal cancer: A literature review 124
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 123
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 122
Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. 121
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 121
Pituitary function and morphology in Fabry disease. 120
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 120
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 119
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 119
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 119
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 119
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease 119
A strange epigastric pain. 118
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 118
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 117
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 116
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 116
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 115
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 112
ROLE OF HFR CARTRIDGE IN THE REMOVAL OF MEDIATORS OF INFLAMMATION IN HEMODIALYSIS PATIENTS 111
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 111
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 110
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 110
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 107
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 105
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 105
ADPKD and metformin: from bench to bedside 105
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 103
Optical Coherence Tomography Angiography Findings in Fabry Disease 103
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 103
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 102
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 101
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 101
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 100
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 100
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 99
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 98
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 97
Immunomodulatory Effect of Continuous Venovenous Hemofiltration during Sepsis: Preliminary Data 97
Atrial septum aneurysm: an unusual manifestation in ADPKD? 97
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 95
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 95
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 95
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study 92
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 91
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 91
Renal denervation in ADPKD: an exceptional case 90
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE 88
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 88
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 88
Therapeutic advances in ADPKD: the future awaits 88
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 87
Clinical manifestation of patients with Fabry disease and R356W GLA variant 85
Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease 84
Clinical and Pathophysiologic Correlates of Basilar Artery Measurements in Fabry Disease 83
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study 82
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. 81
Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family 79
The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study 78
Fanconi syndrome with lysinuric protein intolerance 77
Cardiac involvement in Anderson–Fabry disease. The role of advanced echocardiography 74
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial 73
Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis 72
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients 71
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 68
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 67
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease 67
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial 67
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease 63
A pilot study of circulating microRNAs as potential biomarkers of Fabry disease 63
Does Physical Exercise Ameliorate Chronic Kidney Disease-Related Complications? The Case of Anaemia and Chronic Kidney Disease-Mineral Bone Disorder 60
Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease 60
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. 60
Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience 58
Does left ventricular function predict cardiac outcome in Anderson-Fabry disease? 58
Atheroembolic Kidney Disease and Atypical Hemolytic Uremic Syndrome: Two Sides of the Same Coin? 54
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature 54
Cholesterol crystal embolism treatment: from bench to bedside 53
Semaglutide in Non-Diabetic Patients with Fabry Disease 52
Polycystic pancake kidney 51
Nutritional treatment in chronic kidney disease: the concept of nephroprotection. 51
Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease 51
New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review 50
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? 50
The potential use of biomarkers in predicting contrast-induced acute kidney injury. 44
The Case | A patient with autosomal dominant polycystic kidney disease with an atypical kidney magnetic resonance image 41
Acute Kidney Injury in COVID-19 Pandemic 38
“Voclosporin in late onset lupus nephritis with anti-PLA2R antibodies” 36
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease Case Reports 36
Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin 33
Comment on: Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study 27
Totale 9.056
Categoria #
all - tutte 29.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.174


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021230 0 0 0 0 0 0 10 16 34 13 23 134
2021/2022450 4 0 5 4 7 11 28 18 33 52 116 172
2022/2023571 75 44 26 41 55 69 9 57 97 53 30 15
2023/2024561 23 92 41 38 35 76 6 62 15 12 118 43
2024/20252.752 125 97 23 54 53 187 262 161 202 275 1.049 264
2025/20263.726 666 474 570 610 1.118 249 39 0 0 0 0 0
Totale 9.056